Thus, reliable biomarkers that correlate with fibrosis stage and progression of liver disease are in demand in order to predict outcome and to stage disease without the need for invasive liver biopsy, and this trial will aid in investigating the role of VAP-1 in liver fibrosis and its potential as a therapeutic target and biomarker. The gene discussed is AOC3; the disease is Hepatic fibrosis.